ESMO 2023

Remarkable efficacies in patients with HER2+ mBC with brain metastases

DATO-DX - where is it going?

Preoperative checkpointinihition in ER+ disease

My highlights of ESMO23 in metastatic breast cancer

Highlights in eBC

5 year follow-up

Lu-PSMA leads forward

Early use of enzalutamide in advanced prostate cancer

New 3rd line therapy for RCC

When the history of ADC is written: Redefining first-line standard of care in mUC!

Clearing up non-clear cell RCC

The FGFR story in bladder cancer at ESMO23

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

My highlights from ESMO 2023

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

ALINA - immediate change of practice!

Tarlatamab in SCLC

New and better biomarkers are needed!

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

Anticipated updates and exciting new data for checkpointinhibitors

What is your definition of triple-negative breast cancer?

What was the most exciting news at ESMO23?

5 year follow-up

New data on neoadjuvant immunotherapy

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Consolidation of data in early HR+ and triple-negative breast cancer

Ribociclib effective in all subtypes

Carry-over effects in monarchE confirmed

Preoperative checkpointinihition in ER+ disease

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Negative EFS results from NeoTrip

Pembrolizumab solidifies as SOC in early-stage TNBC

HR+ study with > 20 % PCR

Analysis of tumour microenvironment and immunophenotype in TNBC

Clinically relevant effect of pembro also in PCR

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Highlights in eBC

My highlights of ESMO23 in early breast cancer

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Our guidelines are correct

ER-low corresponds diagnostically to ER-0 breast cancer

MonarchE - trial update

Immunoncology in eBC - triple negative and more?

Detailed view of nodal-negative patients

Studio NeoTrip: negativi i risultati

Nouvelles données sur l'immunothérapie néoadjuvante

Punti salienti in eBC

MonarchE - mise à jour de l'essai

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

New targets, new linker, new ADCs - much more to learn with new therapies!

What was the most exciting news at ESMO23?

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

Improvement of therapy outcome by app-based patient education

How to organize a molecular tumorboards in breast cancer?

New ADC for metastatic breast cancer?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Can surgery be spared following primary systemic therapy?

Even more new generation ADCs in breast cancer?

Still on track for success in HER2-low MBC

HS20089 - a novel ADC is coming for TNBC

Abemaciclib remains consistent in 5-year follow-up

Dato-DXd - new player in advanced luminal disease

HER2DX in the PHERgain trial

New ADC in HR+ disease

T-DXd - new standard of care for brain mets?

Fulvestran better than anastrozole, but no survival benefit

Our guidelines are correct

Patient-centered molecular medicine - a new approach

Duvalumab + Dato-DXd effective

OP seems to be dispensable for super responders

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

T-DXd also effective for brain metastases

Highlights in mBC

ADC + Immunotherapy - the BEGONIA study paradigm

Benefit for SG even after intensive pretreatment

Robust data from the monarchE

DATO-DX - where is it going?

Improved oncological therapy with the smartphone

My highlights of ESMO23 in metastatic breast cancer

TROP2 expression as a potential mechanism of resistance in HER2+ patients

TULIP: Trastuzumab duocarmazine without OS benefit

T-DXd in HER2+ patients with brain metastases

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Lo studio BEGONIA nelle paziento con tumore triplo negativo

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

HER2DX en el estudio PHERgain

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

Punti salienti in mBC

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

What is the future of immune therapy in prostate cancer?

Targeted therapy will move forward - but more robust data is needed.

Should we use zoledronic acid in all ADT patients?

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

Longterm toxicity of adjuvant RT after prostatectomy

Combination of radioligand therapy with chemotherapy useful

CXCR2 inhibitor in PCa

Negative data for pembrolizumab in mHSCPC & mCRPC

Lu-PSMA leads forward

TITAN: ultra-low PSA = best prognosis

EMBARK - Quality of Life

Big data and AI prediction tools

ENZA P:Trial and controversies

EMBARK expands ENZA indication to PCa

Embark without fear

PSMAfore unleashes urooncologic opportunity

Brave New World in mCRPC

Early use of enzalutamide in advanced prostate cancer

Osteoprotection at mHSPC

Immunotherapy in metastatic PCa

Salvage radiotherapy the new standard

PSMA FORE: Trial and controversies

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

IO therapy in metastatic prostate cancer.

RADICALS RT: Trial and controversies

Precision medicine at mCRCP

EMBARK och livskvalitet

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

Big Data och AI för prediktion vid prostatacancer

Immunterapi vid prostatacancer

CXCR2 hämmare och prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Part1: New standard of care in first line urothelial cancer?!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part 2: New standard of care in first line urothelial cancer!

Chemo-IO establishes itself in the first-line treatment of bladder cancer

When the history of ADC is written: Redefining first-line standard of care in mUC!

DAD, DAD-IO

Amazing new data in bladder cancer

EV + Pembro as standard of care in first-line therapy of bladder cancer

New SoC in firstline bladder cancer

Unique bladder delivery system of gemcitabine herolds remarkable response

The FGFR story in bladder cancer at ESMO23

FGFR inhibitors: What is the best scenario for this family of compounds?

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Where does the future therapy go in renal cell carcinoma?

Important new treatment option but only for subset of patients?

Is de-escalating therapy ready for prime-time?

Belzutifan - whats next kidney cancer?

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

Belzutifan in later lines of therapy

Kidney cancer highlights at ESMO23

New mode of action in mRCC - ready for prime time?

Intermittent therapy also possible with TKIs

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Circulating DNA in AEGEAN trial

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Scene is set for inductive immunotherapy

My highlights from ESMO 2023

Big improvements in early stage and a subset of metatstic NSCLC

Substantial improvement in local regional NSCLC

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - immediate change of practice!

Les points forts de l'ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

I miei punti salienti di ESMO 2023

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Evolving landscape of ADCs

Activating EGFR-mutation - what's coming up?

ESMO2023-impact on everyday practice!

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Does immunotherapy still have a place in EGFR-positive mNSCLC?

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Changing treatment landscape in EGFR-mutated NSCLC

PAPILLON - bringing together therapy for the 1st line

Treatment sequences for EGFR-mutated Patients

My highlights from ESMO 2023

NRG fusions: a new drugable target?

By unanimous decision and still the champion – docetaxel!

Adagrasib + pembrolizumab in patients with KRASG12C mutation

LIBRETO - a positive study, but was it necessary?

Brain metastases – options to improve the systemic treatment

Do ADCs have brain activity?

MARIPOSA II: Trial and controversies

MARIPOSA: Trial and controversies

Big improvements in early stage and a subset of metatstic NSCLC

Substantial improvement in rare alterations

TROPION-Lung01: positive development

Amivantamab upfront? MARIPOSA trial

Amivantamab at progression? MARIPOSA-2 trial

Practice changing results on exon 20 insertion mNSCLC

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Les points forts de l'ESMO 2023

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

I miei punti salienti di ESMO 2023

Quelles séquences thérapeutiques pour les patients EGFR mutés

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Amivantamab at progression? MARIPOSA-2 trial

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Amivantamab upfront? MARIPOSA trial

Impact of T-cell engagers in SCLC

A new option in relapsed SCLC

New hope for patients with SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

First data on luveltamab in multiline treatment for endometrial cancer

New data on H&N Cancer

New data on sarkomas

Precision oncology in CUP

Evolution of the revolution - the RUBY trial

Update on gynaecological cancers

PCO Therapeutics